Joshua Schultz serves as Chief Executive Officer of Cytel. He is an accomplished leader with a 20-year track record of success in life sciences and clinical research organizations. Prior to joining Cytel he served as an Officer of PAREXEL and Senior Vice President for PAREXEL’s Access business unit.
Joshua has built and led groups for services spanning the development lifecycle, including study-start up, late phase trials and market access. His achievements include the development of novel approaches to building high value strategic partnerships with life science companies and creating innovative operational models that leverage real world data and related technologies.
Prior to joining PAREXEL, he served as Vice President of Corporate Development at Veritas Medicine, which he co-founded. Previously, he worked at Mercer Management Consulting, where he developed growth strategies for Fortune 500 companies.
Joshua holds a B.S.E. in Finance from the Wharton School of Business, a B.A. in International Relations from the University of Pennsylvania, and a Masters of Philosophy in International Relations from the University of Cambridge, UK.